🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Cholecalciferol

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 other completed

    1 trial

  2. Cholecalciferol

    United Therapeutics Europe Ltd

    Asthma

    phase 3 other completed

    1 trial

  3. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial

  4. Cholic Acid

    Mirum Pharmaceuticals International B.V.

    Bile Acid Synthesis Defect

    phase 3 small molecule completed

    1 trial

  5. Cholic Acids

    Mirum Pharmaceuticals International B.V.

    Infantile Refsum's Disease

    phase 3 small molecule completed

    1 trial

  6. Cholic acid

    Mirum Pharmaceuticals International B.V.

    Inborn Errors of Bile Acid Synthesis

    phase 3 small molecule completed

    1 trial

  7. Cibinqo 100 mg film-coated tablets, Placebo for Abrocitinib 100mg tablet

    Pfizer Australia Pty Ltd

    Moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  8. Cilostazol-Elpen 100 mg Tabletten, Placebo de Cilostazol-Elpen 100mg, comprimé

    Pari Pharma GmbH

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  9. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  10. Cinryze®

    Takeda

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  11. Cipaglucosidase Alfa

    AMICUS THERAPEUTICS PTY LTD

    Pompe Disease (Late-onset)

    phase 3 mab completed

    1 trial

  12. Cisplatin

    Children's Hospital of Fudan University

    Localized Osteosarcoma

    phase 3 small molecule completed

    1 trial

  13. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  14. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  15. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  16. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  17. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  18. Clamp-Crushing technique

    The First People's Hospital of Lianyungang

    Hepatobiliary Disease

    phase 3 other completed

    1 trial

  19. Clascoterone

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  20. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  21. Clifutinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Leukemia, Acute Myeloid (AML)

    phase 3 small molecule active

    1 trial

  22. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  23. Clopidogrel

    Eli Lilly and Company

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  24. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources